Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
144.8 USD | +1.92% | +2.35% | +14.99% |
Sales 2024 * | 425M 454M | Sales 2025 * | 742M 793M | Capitalization | 7.73B 8.26B |
---|---|---|---|---|---|
Net income 2024 * | -236M -252M | Net income 2025 * | 10M 10.69M | EV / Sales 2024 * | 19.1 x |
Net Debt 2024 * | 390M 416M | Net Debt 2025 * | 323M 345M | EV / Sales 2025 * | 10.9 x |
P/E ratio 2024 * |
-31.6
x | P/E ratio 2025 * |
3,235
x | Employees | 879 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 10.4% |
Latest transcript on Ascendis Pharma A/S
1 day | +1.92% | ||
1 week | +2.35% | ||
Current month | -4.19% | ||
1 month | -0.13% | ||
3 months | +6.10% | ||
6 months | +66.20% | ||
Current year | +14.99% |
Managers | Title | Age | Since |
---|---|---|---|
Jan Mikkelsen
FOU | Founder | 65 | 06-08-31 |
Scott Smith
DFI | Director of Finance/CFO | 50 | 16-08-07 |
Stina Singel
CTO | Chief Tech/Sci/R&D Officer | 50 | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jan Mikkelsen
FOU | Founder | 65 | 06-08-31 |
Albert Cha
CHM | Chairman | 51 | 14-10-31 |
General Counsel | 53 | 07-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.96% | 11 M€ | -6.03% | - | |
0.48% | 0 M€ | 0.00% | - | |
0.45% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 144.8 | +1.92% | 220,120 |
24-04-22 | 142.1 | +1.38% | 245,698 |
24-04-19 | 140.2 | -0.51% | 280,701 |
24-04-18 | 140.9 | -0.90% | 222,169 |
24-04-17 | 142.2 | +0.47% | 299,396 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.99% | 8.27B | |
-0.49% | 105B | |
+3.31% | 97.5B | |
+3.17% | 22.19B | |
-16.16% | 21.33B | |
-7.35% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |
- Stock Market
- Equities
- ASND Stock